Difficulty: Medium
Average Score: 80%
Practice
Concerning fondaparinux, choose the WRONG answer:
Correct answer
C
Rationale
In this scenario, the correct answer is C) Given orally. Fondaparinux is a synthetic anticoagulant that works by indirectly inhibiting factor Xa. It is administered subcutaneously, not orally. This is an important distinction to understand in clinical practice.
Option A, Indirectly inhibits factor Xa, is correct because fondaparinux works by binding to antithrombin III, leading to inhibition of factor Xa.
Option B, Not antagonized by protamine sulfate, is correct because fondaparinux does not interact with protamine sulfate, unlike heparin which can be reversed with protamine sulfate.
Option D, Used in heparin-induced thrombocytopenia, is correct because fondaparinux is often used as an alternative in patients with heparin-induced thrombocytopenia due to its mechanism of action not involving heparin.
Understanding the specific characteristics and administration route of different anticoagulants is crucial for healthcare professionals to make informed decisions in managing patients requiring anticoagulation therapy. This knowledge ensures safe and effective treatment outcomes for patients.
Option A, Indirectly inhibits factor Xa, is correct because fondaparinux works by binding to antithrombin III, leading to inhibition of factor Xa.
Option B, Not antagonized by protamine sulfate, is correct because fondaparinux does not interact with protamine sulfate, unlike heparin which can be reversed with protamine sulfate.
Option D, Used in heparin-induced thrombocytopenia, is correct because fondaparinux is often used as an alternative in patients with heparin-induced thrombocytopenia due to its mechanism of action not involving heparin.
Understanding the specific characteristics and administration route of different anticoagulants is crucial for healthcare professionals to make informed decisions in managing patients requiring anticoagulation therapy. This knowledge ensures safe and effective treatment outcomes for patients.